Home / Training / Manuals / Atlas of visual inspection of the cervix with acetic acid for screening, triage, and assessment for treatment

Atlas of visual inspection of the cervix with acetic acid for screening, triage, and assessment for treatment

Neoplastic changes of the cervical epithelium Ė Genesis of cervical cancer


The natural history of cervical cancer extends over a few decades, starting with infection with human papillomavirus (HPV). HPV is a very common sexually transmitted infection. There are about 15 types of HPV that can cause cervical cancer and other cancer types (anal, vulvar, vaginal, or penile cancer); these are called high-risk HPV types. Women are usually infected with HPV after the onset of sexual activity. Most women clear the infection as they develop natural immunity against the virus. However, a small proportion of women infected with high-risk HPV cannot clear the infection, and they are at high risk of developing cervical cancer. The persistence of infection first leads to the development of a premalignant condition, known as cervical intraepithelial neoplasia (CIN). A similar premalignant lesion that develops over the columnar epithelium is known as adenocarcinoma in situ (AIS). If it remains undetected and is left untreated, CIN or AIS may lead to invasive cervical cancer after 5 Ė10 years.

A few facts about HPV:

  • HPV is a double-stranded DNA virus.
  • More than 200 subtypes of HPV have been identified, of which 15 types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82) are considered to be high-risk or oncogenic types, because they are associated with cervical cancers.
  • HPV is the most common sexually transmitted infection in men and women.
  • Most HPV infections clear because of natural immunity; cervical cancer is a rare outcome of HPV infections.
  • HPV types 16 and 18 are responsible for about 65Ė80% of cervical cancers worldwide.
  • High-risk HPV is responsible for both squamous cell carcinoma and adenocarcinoma.
  • HPV is also responsible for genital warts, which are benign protuberances seen on the external genitalia, vagina, and cervix.
  • High-risk HPV has been implicated in other cancer types, such as vaginal and vulvar cancers in females, penile cancers in males, and anal and oropharyngeal cancers in both sexes.

Cervical cancer is predominantly of two types: squamous cell cancer (which arises from the squamous epithelium) and adenocarcinoma (which arises from the columnar epithelium). Each type of cancer is preceded by the occurrence of a precancerous change of the epithelium. The precursor of squamous cell cancer is known as cervical intraepithelial neoplasia (CIN), and that of adenocarcinoma is known as adenocarcinoma in situ (AIS). Squamous cell cancers are the most common, accounting for 80Ė90% of all cervical cancers. Hence, CIN is much more common than AIS.

Cervical cancer has a slow natural history. Women with CIN or AIS do not have any symptoms. There are appropriate tests that, when administered routinely to women after a certain age, are capable of detecting the precancers. Treatment of precancers may cure about 90% of them, and the women will be prevented from developing cervical cancer in the future. This is the basic principle of cervical cancer screening. Regular screening of women with an appropriate test starting at age 25 or 30 years, followed by treatment of the CIN or AIS lesions detected through screening, can significantly reduce the incidence of cervical cancer in the population. In countries with well-organized screening programmes, in which women are systematically invited to undergo a screening test at an interval of 3Ė5 years, there have been drastic reductions in both the incidence of cervical cancer and mortality from the disease. The most commonly used cervical cancer screening tests are the Pap smear (cytology), VIA, and HPV detection tests.

The next section provides more information about cervical intraepithelial neoplasia (CIN).


Click on the pictures to magnify and display the legends
IARC, 150 Cours Albert Thomas, 69372 Lyon CEDEX 08, France - Tel: +33 (0)4 72 73 84 85 - Fax: +33 (0)4 72 73 85 75
© IARC 2021 - All Rights Reserved.